BETA DRUGS
Quarterly Results Analysis [Jun2026]
BETA DRUGS Quarterly Results
| Consolidated | Jun2026 UnAudited |
Mar2026 UnAudited |
Dec2025 Audited |
Jun2025 UnAudited |
Mar2025 UnAudited |
Dec2024 Audited |
|---|---|---|---|---|---|---|
| Revenues | ₹126 Cr | ₹94 Cr | ₹87 Cr | ₹100 Cr | ₹94 Cr | ₹88 Cr |
| Expenses | ₹98 Cr | ₹76 Cr | ₹70 Cr | ₹81 Cr | ₹76 Cr | ₹70 Cr |
| Operating Income | ₹27 Cr | ₹18 Cr | ₹17 Cr | ₹20 Cr | ₹17 Cr | ₹18 Cr |
| Other Income | ₹2 Cr | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹1 Cr |
| Interest | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| Depreciation | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr |
| Profit Before Tax | ₹22 Cr | ₹12 Cr | ₹10 Cr | ₹16 Cr | ₹12 Cr | ₹12 Cr |
| Profit After Tax | ₹16 Cr | ₹9 Cr | ₹9 Cr | ₹12 Cr | ₹9 Cr | ₹9 Cr |
| EPS | ₹14.25 | ₹8.93 | ₹8.40 | ₹11.59 | ₹8.95 | ₹8.86 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| BETA DRUGS | -5.1% | 7% | 32.4% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.8% | 3.5% | 14.7% |
| DIVIS LABORATORIES | -1% | 7.3% | 7.6% |
| TORRENT PHARMACEUTICALS | -0.9% | 10.1% | 44.6% |
| CIPLA | -2.1% | -1.8% | -6% |
| DR REDDYS LABORATORIES | -5.8% | -13.2% | -7.7% |
| MANKIND PHARMA | -2.4% | 1.2% | -3.2% |
| LUPIN | -4.4% | 0.1% | 22.5% |
| ZYDUS LIFESCIENCES | -3.3% | 0.9% | 13.4% |
BETA DRUGS Quarterly Revenues
| Revenues | |
|---|---|
| Q-o-Q | 33.61 % |
| Y-o-Y | 33.90 % |
| Quarters | Revenues | % Change | |
|---|---|---|---|
| Jun2026 | ₹126 Cr | 33.61 | |
| Mar2026 | ₹94 Cr | 7.67 | |
| Dec2025 | ₹87 Cr | -12.91 | |
| Jun2025 | ₹100 Cr | 6.87 | |
| Mar2025 | ₹94 Cr | 6.20 | |
| Dec2024 | ₹88 Cr | - | |
BETA DRUGS Quarterly Operating Profit
| Operating Profit | |
|---|---|
| Q-o-Q | 54.81 % |
| Y-o-Y | 57.79 % |
| Quarters | Operating Profit | % Change | |
|---|---|---|---|
| Jun2026 | ₹27 Cr | 54.81 | |
| Mar2026 | ₹18 Cr | 4.08 | |
| Dec2025 | ₹17 Cr | -13.80 | |
| Jun2025 | ₹20 Cr | 13.61 | |
| Mar2025 | ₹17 Cr | -6.00 | |
| Dec2024 | ₹18 Cr | - | |
| Operating Margins | |
|---|---|
| Q-o-Q | 15.90 % |
| Y-o-Y | 17.84 % |
| Quarters | Operating Margin% | % Change | |
|---|---|---|---|
| Jun2026 | 21.8% | 15.90 | |
| Mar2026 | 18.81% | -3.34 | |
| Dec2025 | 19.46% | -1.02 | |
| Jun2025 | 19.66% | 6.27 | |
| Mar2025 | 18.5% | -11.48 | |
| Dec2024 | 20.9% | - | |
BETA DRUGS Quarterly Profit After Tax
| Profit After Tax(PAT) | |
|---|---|
| Q-o-Q | 82.15 % |
| Y-o-Y | 82.48 % |
| Quarters | Profit After Tax | % Change | |
|---|---|---|---|
| Jun2026 | ₹16 Cr | 82.15 | |
| Mar2026 | ₹9 Cr | 6.26 | |
| Dec2025 | ₹9 Cr | -27.20 | |
| Jun2025 | ₹12 Cr | 29.50 | |
| Mar2025 | ₹9 Cr | 0.97 | |
| Dec2024 | ₹9 Cr | - | |
| PAT Margins | |
|---|---|
| Q-o-Q | 36.34 % |
| Y-o-Y | 36.34 % |
| Quarters | PAT Margin(%) | % Change | |
|---|---|---|---|
| Jun2026 | 13.13 % | 36.34 | |
| Mar2026 | 9.63 % | -1.33 | |
| Dec2025 | 9.76 % | -16.37 | |
| Jun2025 | 11.67 % | 21.18 | |
| Mar2025 | 9.63 % | -4.94 | |
| Dec2024 | 10.13 % | - | |
BETA DRUGS Quarterly Earnings Per Share (EPS)
| EPS | |
|---|---|
| Q-o-Q | 59.57 % |
| Y-o-Y | 59.22 % |
| Quarters | EPS | % Change | |
|---|---|---|---|
| Jun2026 | ₹14.25 | 59.57 | |
| Mar2026 | ₹8.93 | 6.31 | |
| Dec2025 | ₹8.4 | -27.52 | |
| Jun2025 | ₹11.59 | 29.50 | |
| Mar2025 | ₹8.95 | 1.02 | |
| Dec2024 | ₹8.86 | - | |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD